Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-103 in Adult Patients With Mesothelin-Expressing Advanced or Metastatic Solid Tumors
NCT05164666Phase 1Terminated
- Sponsor
- Takeda
- Start
- Jan 2022
- Primary completion
- Feb 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAK-103 in solid tumor, sponsored by Takeda. Primary endpoints: Dose-Limiting Toxicities at 28 days, Treatment-emergent Adverse Events at 24 months and 1 more. Started Jan 2022; status: terminated.
02
Drugs
TAK-103
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05164666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05164666.